In search of new lead compounds for trypanosomiasis drug design: a protein structure-based linked-fragment approach

J Comput Aided Mol Des. 1992 Apr;6(2):131-47. doi: 10.1007/BF00129424.

Abstract

A modular method for pursuing structure-based inhibitor design in the framework of a design cycle is presented. The approach entails four stages: (1) a design pathway is defined in the three-dimensional structure of a target protein; (2) this pathway is divided into subregions; (3) complementary building blocks, also called fragments, are designed in each subregion; complementarity is defined in terms of shape, hydrophobicity, hydrogen bond properties and electrostatics; and (4) fragments from different subregions are linked into potential lead compounds. Stages (3) and (4) are qualitatively guided by force-field calculations. In addition, the designed fragments serve as entries for retrieving existing compounds from chemical databases. This linked-fragment approach has been applied in the design of potentially selective inhibitors of triosephosphate isomerase from Trypanosoma brucei, the causative agent of sleeping sickness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Binding Sites
  • Databases, Factual
  • Drug Design*
  • Humans
  • Lead / chemistry*
  • Models, Molecular
  • Molecular Structure
  • Organometallic Compounds / chemistry
  • Proteins / chemistry
  • Triose-Phosphate Isomerase / antagonists & inhibitors
  • Triose-Phosphate Isomerase / chemistry
  • Trypanocidal Agents / chemistry*
  • Trypanosoma / drug effects
  • Trypanosoma / enzymology
  • Trypanosomiasis / drug therapy

Substances

  • Organometallic Compounds
  • Proteins
  • Trypanocidal Agents
  • Lead
  • Triose-Phosphate Isomerase